On the 26th (local time), the European Medicines Agency (EMA) announced that the antibody treatment 'REGN-COV2,' developed by the US biotech company Regeneron, can be used to treat COVID-19 patients who do not require oxygen therapy but are at high risk of progressing to severe illness.
According to major foreign media on the day, the EMA explained that this recommendation "can be used as guidance in individual European Union (EU) member states to review the possibility of using this treatment before marketing authorization is granted."
This antibody treatment is currently undergoing a rolling review. Rolling review is a procedure to expedite the evaluation of promising medicines or vaccines during public health emergencies such as the global COVID-19 pandemic.
'REGN-COV2' received emergency use authorization from the US Food and Drug Administration (FDA) in November last year.
It is a treatment combining two monoclonal antibodies, developed by analyzing and evaluating antibodies from the blood of recovered COVID-19 patients to select only those capable of neutralizing the virus. It was used when former US President Donald Trump was infected with COVID-19.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
